FDA accuses firm of selling unapproved drugs
This article was originally published in The Tan Sheet
Executive Summary
Under a consent decree with FDA, Risingsun Health and the Center for Complimentary and Alternative Health in Livingston, Mont., agree to hire an independent expert for pre-market review of product claims and to certify the claims are compliant. The decree, which also prohibits the firms from selling unapproved new drugs, was filed in the U.S. District Court for the District of Montana and resolves charges the firm sold ineffective products. Prior to signing the decree, Risingsun made and distributed unapproved new drugs, including Black Salve, Cancema and Can-Support, purported to treat cancer, asthma, anemia and epilepsy, FDA said Oct. 13